Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
AstraZeneca
Accenture
Chinese Patent Office
Johnson and Johnson
QuintilesIMS
Mallinckrodt
Argus Health
Cipla

Generated: October 21, 2017

DrugPatentWatch Database Preview

Helsinn Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for HELSINN HLTHCARE, and when can generic versions of HELSINN HLTHCARE drugs launch?

HELSINN HLTHCARE has three approved drugs.

There are eighteen US patents protecting HELSINN HLTHCARE drugs.

There are one hundred and seventy-eight patent family members on HELSINN HLTHCARE drugs in sixty-three countries and fourteen supplementary protection certificates in ten countries.

Summary for Applicant: Helsinn Hlthcare

International Patents:178
US Patents:18
Tradenames:2
Ingredients:2
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► SubscribeY► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Helsinn Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn Hlthcare
AKYNZEO
netupitant; palonosetron hydrochloride
CAPSULE;ORAL205718-001Oct 10, 2014► Subscribe► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-002Feb 29, 2008► Subscribe► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
INJECTABLE;INTRAVENOUS021372-001Jul 25, 2003► Subscribe► Subscribe
Helsinn Hlthcare
ALOXI
palonosetron hydrochloride
CAPSULE;ORAL022233-001Aug 22, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Helsinn Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,479,483 4-phenyl-pyridine derivatives► Subscribe
9,308,266Liquid pharmaceutical formulations of palonosetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Helsinn Hlthcare Drugs

Country Document Number Estimated Expiration
South Korea101113084► Subscribe
Serbia53869► Subscribe
San MarinoT201400112► Subscribe
Spain2315635► Subscribe
Serbia53491► Subscribe
Turkey200000520► Subscribe
Slovakia287912► Subscribe
Austria277905► Subscribe
CroatiaP20161277► Subscribe
Poland378398► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Helsinn Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00044Denmark► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150527
/2005Austria► SubscribePRODUCT NAME: PALONOSETRON, DESSEN SALZE UND STEREOISOMERE; REGISTRATION NO/DATE: EU/1/04/306/001 20050322
2015036Lithuania► SubscribePRODUCT NAME: NETUPITANTUM; REGISTRATION NO/DATE: EU/1/15/1001 20150527
90040-0Sweden► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
C/GB05/032United Kingdom► SubscribePRODUCT NAME: PALONOSETRON OR AN ISOMER, MIXTURE OF ISOMERS, N-OXIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/306/001 20050322
2015 00044Denmark► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
2015036,C1035115Lithuania► SubscribePRODUCT NAME: NETUPITANTAS; REGISTRATION NO/DATE: EU/1/15/1001 20150527
C0049France► SubscribePRODUCT NAME: NETUPITANT OU L'UN DE SES SELS D'ADDITION D'ACIDES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1001 20150529
1035115/01Switzerland► SubscribePRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
0758Netherlands► SubscribePRODUCT NAME: NETUPITANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/15/1001 20150527
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Julphar
Teva
McKesson
QuintilesIMS
Medtronic
Novartis
Daiichi Sankyo
Chubb
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot